CN105030841A

CN105030841A - Application of Akkermansia muciniphila BAA-835 strain

Info

Publication number: CN105030841A
Application number: CN201510521005.3A
Authority: CN
Inventors: 宁光; 王计秋; 洪洁; 王卫庆; 刘瑞欣; 赵少倩; 刘�文; 石娟
Original assignee: Ruinjin Hospital Affiliated to Shanghai Jiaotong University School of Medicine Co Ltd
Current assignee: Ruinjin Hospital Affiliated to Shanghai Jiaotong University School of Medicine Co Ltd
Priority date: 2015-08-24
Filing date: 2015-08-24
Publication date: 2015-11-11

Abstract

The invention belongs to the field of probiotic application and particularly relates to application of an Akkermansia muciniphila BAA-835 strain in preparation for treating or preventing diabetes mellitus. According to the application, controlled experiments on C57/BL6 male SPF mouse littermates which are randomly divided into a control group and a strain gavage group are adopted, an Akkermansia muciniphila BAA-835 strain suspension gavage test is given to the strain gavage group once a day for 5 weeks. By means of the tests, the glucose tolerance area under the curve of the strain gavage group is reduced by 21.3 percent in comparison with that of the control group, which verifies that the Akkermansia muciniphila BAA-835 strain has an effect of improving glycometabolism and can be applied to the field of treatment or prevention of diabetes mellitus.

Description

The application of Akkermansia muciniphila BAA-835 bacterial strain

Technical field

The invention belongs to the application of probiotic bacteria, particularly AkkermansiamuciniphilaBAA-835 bacterial strain is in treatment or the application in preventing diabetes.

Background technology

Due to the change of modern's life style and dietary structure, the sickness rate of diabetes increases day by day.Diabetes, as the risk factors of cardiovascular event, tumor etc., have become global Community health's problem.At present, for diabetes, except five traditional frame carriages and diabetes later stage application insulin, not permanently effective treatment means.After GORDON laboratory proposition intestinal microbial population in 2004 can regulate lipid metabolism as an envirment factor, intestinal microbial population emerges in an endless stream with correlation research that is fat and diabetes in recent years.2012, Shenzhen Hua Da utilizes and has carried out sequencing analysis based on the new-generation sequencing technology of shotgun sequencing to 345 Chinese intestinal specimen, find that the patient suffering from type 2 diabetes mellitus exists obvious alteration of intestinal flora, show as the while that the flora abundance of producing butyrate lowering and increase with opportunist.These all may become the mark and potential therapy target of differentiating type 2 diabetes mellitus.Find that some can fall hypoglycemic bacteria types, as LactobacillusrhamnosusGG based on the research in Mice Body.This this section of article adopts the administering mode of db mouse stomach, gives physiological saline solution or bacterial suspension respectively, and every day, gavage, continued 4 weeks, and record body weights, surveys glucose tolerance in mice after off-test.Result shows that this antibacterial continues carbohydrate metabolism and the body weight increase that gavage can improve db mice.The exploitation probiotic bacteria intervention diabetes that are found to be of these researchs provide important tests foundation and technological means.

Summary of the invention

The object of this invention is to provide AkkermansiamuciniphilaBAA-835 bacterial strain preparation treatment or in preventing diabetes in application, relate to the application of the aspect such as medicine, pharmaceutical composition, food and feeds for the treatment of or preventing diabetes.This bacterial strain reduces mouse blood sugar, improves the carbohydrate metabolism of mice.Widen the scope of application of AkkermansiamuciniphilaBAA-835 bacterial strain, the application developing a kind for the treatment of that is effective, new, that have no side effect and prevent diabetes.

The present invention relates to the application that AkkermansiamuciniphilaBAA-835 bacterial strain is treated in preparation or prevented diabetes in medicine.Prove through experiment, AkkermansiamuciniphilaBAA-835 bacterial strain has reduction mouse blood sugar, improves the beneficial effect of glucose tolerance in mice, so, this bacterial strain is the probiotic bacteria that diabetes are intervened, and can be applied in the medicine prepared and treat or prevent diabetes.

Treatment or the pharmaceutical composition prevented diabetes, is characterized in that, comprising: AkkermansiamuciniphilaBAA-835 bacterial strain and pharmaceutically acceptable adjuvant.Preferably, when this treatment or the pharmaceutical composition prevented diabetes are solid-state, in described pharmaceutical composition, 10 are comprised ⁷-10 ¹²the AkkermansiamuciniphilaBAA-8352 bacterial strain of cfu/g.

When this treatment or the pharmaceutical composition prevented diabetes are liquid, in described pharmaceutical composition, comprise 10 ⁷-10 ¹¹the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/mL.

Described pharmaceutically acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.Through zoopery, this pharmaceutical composition can be treated or prevent diabetes.

The medicine that aforementioned pharmaceutical compositions can be prepared into treatment or prevent diabetes.Preferably, described medicine is at least one dosage form in granule, capsule, tablet, powder agent, oral liquid, suspension and Emulsion.

Treatment or the food prevented diabetes, is characterized in that, comprise acceptable adjuvant in AkkermansiamuciniphilaBAA-835 bacterial strain and bromatology.Preferably, when described treatment or the food prevented diabetes are solid-state, in described food, 10 are comprised ⁷-10 ¹²the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/g.

When this treatment or the food prevented diabetes are liquid, in described food, comprise 10 ⁷-10 ¹¹the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/mL.

In described bromatology, acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.

Treatment or the feedstuff prevented diabetes, is characterized in that, comprise acceptable adjuvant in AkkermansiamuciniphilaBAA-835 bacterial strain and feedstuff.

Beneficial effect of the present invention is: the invention provides the novelty teabag that AkkermansiamuciniphilaBAA-835 bacterial strain is treated in preparation or prevented diabetes in medicine, by experiment, demonstrate AkkermansiamuciniphilaBAA-835 bacterial strain very effective to glycemic control, and filling bacterium glucose tolerance in mice area under curve reduces 21.3% than control group mice.So, medicine, pharmaceutical composition that AkkermansiamuciniphilaBAA-835 bacterial strain may be used for treating or prevent diabetes, in food and feeds, widen the application of AkkermansiamuciniphilaBAA-835 bacterial strain.

Accompanying drawing explanation

Fig. 1 is that mice fills with bacterium after 5 weeks, carbohydrate tolerance comparison diagram.

Fig. 2 is that mice fills with bacterium after 5 weeks, area comparison diagram under glucose tolerance curve.

Detailed description of the invention

Below in conjunction with embodiment, the invention will be further described:

The mouse model used in the present embodiment is: choose C57/BL6 in 10 week age male SPF level mice, all buy from Shanghai Si Laike zoopery company limited.Mice 5 cages are raised in isolation bag, and feed of freely intaking, maintains circadian rhythm.

Bacterial strain information: AkkermansiamuciniphilaBAA-835 bacterial strain is bought from ATCC company of the U.S., name of product: Akkermansia bAA-835.

Embodiment 1

Be divided into matched group at random by brood for male for C57/BL6 SPF level mice and fill with bacterium group, only often organize 8-10, matched group gives aseptic PBS gavage, once a day; Fill with bacterium group and give AkkermansiamuciniphilaBAA-835 strain suspensions according to 2*10 ⁹cfu/ mice, carries out gavage test, once a day.Test 5 weeks.After off-test, detect glucose tolerance in mice situation.

Concrete carbohydrate tolerance situation is as shown in following table 1.

Table 1

As can be seen from the table, after AkkermansiamuciniphilaBAA-835 strain suspensions gavage is carried out to mice, carbohydrate tolerance obviously increases slowly than the mice of matched group, illustrates that AkkermansiamuciniphilaBAA-835 bacterial strain is very effective to the control of blood glucose.Specifically as depicted in figs. 1 and 2.

Area under the glucose tolerance curve of mice is calculated, specifically as shown in table 2:

Table 2

As can be seen from Table 2, after giving mice AkkermansiamuciniphilaBAA-835 strain suspensions gavage, under the glucose tolerance curve of Guan Junzu group, area reduces 21.3%, illustrates that the reduction effect of AkkermansiamuciniphilaBAA-835 bacterial strain to mouse blood sugar is very effective.

The above is preferred embodiment of the present invention, but the present invention should not be confined to the content disclosed in this embodiment.The equivalence completed under not departing from spirit disclosed in this invention so every or amendment, all fall into the scope of protection of the invention.

Claims

The application that 1.AkkermansiamuciniphilaBAA-835 bacterial strain is treated in preparation or prevented diabetes in medicine.
2. the pharmaceutical composition for the treatment of or preventing diabetes, is characterized in that, comprising: AkkermansiamuciniphilaBAA-835 bacterial strain and pharmaceutically acceptable adjuvant.
3. treatment according to claim 2 or the pharmaceutical composition that prevents diabetes, is characterized in that: when this pharmaceutical composition is solid-state, comprise 10 in described pharmaceutical composition ⁷-10 ¹²the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/g; When this pharmaceutical composition is liquid, in described pharmaceutical composition, comprise 10 ⁷-10 ¹¹the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/mL.
4. treatment according to claim 3 or the pharmaceutical composition that prevents diabetes, it is characterized in that, described pharmaceutically acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.
5. the medicine for the treatment of or preventing diabetes, is characterized in that, comprise the pharmaceutical composition any one of claim 2-4.
6. treatment according to claim 5 or the medicine that prevents diabetes, it is characterized in that, described medicine is at least one dosage form in granule, capsule, tablet, powder agent, oral liquid, suspension and Emulsion.
7. the food for the treatment of or preventing diabetes, is characterized in that, comprise acceptable adjuvant in AkkermansiamuciniphilaBAA-835 bacterial strain and bromatology.
8. treatment according to claim 7 or the food that prevents diabetes, is characterized in that, when described food is solid-state, comprise 10 in described food ⁷-10 ¹²the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/g; When this food is liquid, in described food, comprise 10 ⁷-10 ¹¹the AkkermansiamuciniphilaBAA-835 bacterial strain of cfu/mL.
9. treatment according to claim 7 or the food that prevents diabetes, it is characterized in that, in described bromatology, acceptable adjuvant is be selected from least one in carrier, excipient, diluent, lubricant, wetting agent, emulsifying agent, suspension stabiliser, antiseptic, sweeting agent and spice.
10. the feedstuff for the treatment of or preventing diabetes, is characterized in that, comprise acceptable adjuvant in AkkermansiamuciniphilaBAA-835 bacterial strain and feedstuff.